BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
-16.69%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$2.07B
AUM Growth
+$2.07B
(-17%)
Cap. Flow
+$111M
Cap. Flow
% of AUM
5.36%
Top 10 Holdings %
Top 10 Hldgs %
44.14%
Holding
87
New
6
Increased
22
Reduced
12
Closed
8
Top Buys
| 1 |
MoonLake Immunotherapeutics
MLTX
|
$114M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$47.3M |
| 3 |
Repare Therapeutics
RPTX
|
$34M |
| 4 |
Cullinan Oncology
CGEM
|
$27.4M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$25M |
Top Sells
| 1 |
argenx
ARGX
|
$99.7M |
| 2 |
Galapagos
GLPG
|
$64.9M |
| 3 |
Protagonist Therapeutics
PTGX
|
$24.3M |
| 4 |
CALA
Calithera Biosciences, Inc
CALA
|
$21.7M |
| 5 |
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
|
$14.6M |
Sector Composition
| 1 | Healthcare | 99.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Repare Therapeutics
RPTX
$71.7M
| $116M | 5.6% | 8,291,988 +2,433,212 | +42% | +$34M |
|
|
2
MoonLake Immunotherapeutics
MLTX
$3.54B
| $114M | 5.52% | +21,751,284 | New | +$114M |
|
3
Arcus Biosciences
RCUS
$1.13B
| $100M | 4.85% | 3,960,948 | – | – |
|
|
4
Cullinan Oncology
CGEM
$445M
| $96.3M | 4.65% | 7,509,059 +2,139,600 | +40% | +$27.4M |
|
5
GH Research
GHRS
$837M
| $92.6M | 4.47% | 9,275,158 | – | – |
|
6
Merus
MRUS
$4.98B
| $92.4M | 4.46% | 4,081,431 -53,640 | -1% | -$1.21M |
|
7
Kymera Therapeutics
KYMR
$2.95B
| $81.5M | 3.94% | 4,138,758 +552,100 | +15% | +$10.9M |
|
8
Xoma
XOMA
$392M
| $78.7M | 3.8% | 3,530,543 | – | – |
|
9
Relay Therapeutics
RLAY
$619M
| $73.4M | 3.55% | 4,384,805 -145,800 | -3% | -$2.44M |
|
10
Crinetics Pharmaceuticals
CRNX
$2.92B
| $68.6M | 3.31% | 3,678,947 +675,068 | +22% | +$12.6M |
|
11
Kura Oncology
KURA
$686M
| $58.7M | 2.84% | 3,203,783 | – | – |
|
12
Aclaris Therapeutics
ACRS
$209M
| $55.5M | 2.68% | 3,976,543 | – | – |
|
|
CTIC
13
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $53.3M | 2.57% | 8,929,690 | – | – |
|
|
EQRX
14
DELISTED
EQRx, Inc. Common Stock
EQRX
| $49.9M | 2.41% | 10,648,527 -1,377,043 | -11% | -$6.46M |
|
15
Xenon Pharmaceuticals
XENE
$2.98B
| $48.6M | 2.35% | 1,597,966 | – | – |
|
|
16
Ionis Pharmaceuticals
IONS
$6.79B
| $47.3M | 2.28% | +1,276,574 | New | +$47.3M |
|
17
Syndax Pharmaceuticals
SNDX
$1.41B
| $45.3M | 2.19% | 2,356,934 -37,780 | -2% | -$727K |
|
18
Revolution Medicines
RVMD
$7.1B
| $44M | 2.12% | 2,255,588 +445,039 | +25% | +$8.67M |
|
19
iTeos Therapeutics
ITOS
| $39.7M | 1.92% | 1,929,201 +529,000 | +38% | +$10.9M |
|
20
IDEAYA Biosciences
IDYA
$2.15B
| $38.6M | 1.86% | 2,794,859 +1,194,300 | +75% | +$16.5M |
|
|
CNTA
21
Centessa Pharmaceuticals
CNTA
$2.25B
| $33.6M | 1.62% | 6,894,345 +5,138,800 | +293% | +$25M |
|
22
Relmada Therapeutics
RLMD
$37.2M
| $31.5M | 1.52% | 1,659,220 +11,820 | +0.7% | +$224K |
|
|
CINC
23
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $31M | 1.5% | 1,644,393 -90,900 | -5% | -$1.71M |
|
24
Olema Pharmaceuticals
OLMA
$375M
| $31M | 1.5% | 7,611,503 +200,000 | +3% | +$814K |
|
25
4D Molecular Therapeutics
FDMT
$288M
| $28M | 1.35% | 4,007,413 +1,342,892 | +50% | +$9.37M |
|